Table 1. Patient Demographics and Characteristics.
| Variable | Included patients (n = 130) | ≥5-Year follow-up (n = 50) | Excluded patients (n = 458) |
|---|---|---|---|
| Follow-up, mean (SD), y | 4.3 (1.7) | 6.2 (0.7) | NA |
| Age, mean (SD), y | 34.4 (23.8) | 30.1 (22.9) | 39.2 (20.2) |
| Sex, No. (%) | |||
| Female | 101 (78) | 35 (70) | 375 (82) |
| Male | 29 (22) | 15 (30) | 83 (18) |
| Race/ethnicity, No. (%) | |||
| White | 96 (74) | 37 (74) | 335 (73) |
| Hispanic | 19 (15) | 8 (16) | 68 (15) |
| African American | 4 (3) | 1 (2) | 23 (5) |
| Other | 11 (8) | 4 (8) | 32 (7) |
| Age at onset, No. (%) | |||
| Adults | 78 (60) | 26 (52) | 365 (80) |
| Childrena | 52 (40) | 24 (48) | 93 (20) |
| Subtype, No. (%) | |||
| Linear | 72 (55) | 26 (52) | 201 (44) |
| Generalized | 40 (31) | 14 (28) | 142 (31) |
| Other | 18 (14) | 10 (20) | 115 (25) |
| Clinical measures, median (IQR) | |||
| mLoSSI | 5 (1-16) | 5 (2-12) | 10 (0-12) |
| LoSDI | 10 (6-23) | 10 (5-18) | 15 (6-20) |
| PGA-A | 20 (0-50) | 20 (5-55) | 25 (0-40) |
| PGA-D | 30 (20-50) | 40 (20-50) | 28 (10-40) |
| Treatment, No. (%) | |||
| Methotrexate sodium, with or without corticosteroids | 66 (51) | 29 (58) | NA |
| UV-A1 phototherapy | 42 (32) | 17 (34) | NA |
| Topical or none | 22 (17) | 4 (8) | NA |
Abbreviations: IQR, interquartile range; LoSDI, Localized Scleroderma Skin Damage Index; mLoSSI, modified Localized Scleroderma Skin Severity Index; NA, not applicable; PGA-A, Physician’s Global Assessment of Activity; PGA-D, Physician’s Global Assessment of Damage.
a
Children are defined as those younger than 18 years at enrollment.